100%(77)77 out of 77 people found this document helpful
This preview shows page 2 - 4 out of 4 pages.
order to make strategies that are effective for pediatrics, the process of multidisciplinary review needs to be addressed separately for the wide range of age groups that the treatment is intended for, i.e. infancy to adolescence (Flack, et al., 2012). In 1997, the FDA enacted special incentives for commercial pharmaceutical companies that manufacture pediatric medications in order to research off-label uses and safety practices in depth (Flack, et al., 2012). One example of an off-label drug use for a medication that is currently being studied in pediatrics is the fentanyl patch on infants that are withdrawing from opioid exposure in the womb (Molgat-Seon, et al., 2014). Lower doses of the patch that can be weaned down, have helped with safe withdraw for high risk and low birth weight infants in the NICU (Molgat- Seon,et al., 2014).Examples of drugs that require special attention with off label uses in children are with gabapentin and midazolam. Gabapentin has been shown to induce neuropsychiatric events in children three to twelve years of age when used as an adjunctive therapy in the treatment of partial seizures (Flack, et al., 2012). Midazolam used for sedation purposes was shown to have a higher risk of serious and life-threatening adverse events for children with congenital heart disease and pulmonary hypertension (Flack, et al., 2012).